Abstract: Provided is a thermotherapy device, which includes a first housing (10), a second housing (20) disposed under the first housing (10), a transfer plate (30), at both sides of which transfer rollers (31) are provided, and a pair of guide rails (40) that is provided to the second housing (20) and on which the respective transfer rollers (31) of the transfer plate (30) are placed. The pair of guide rails (40) are integrally molded when the second housing (20) is injection-molded. Thus, since the guide rails on which the transfer rollers of the transfer plate travel are integrally molded when the second housing is injection-molded, inefficiency caused by mounting separate rails as in the related art is removed, and thereby assemblability, productivity, and economic efficiency of the thermotherapy device can be improved.

Abstract: A compound, a stereoisomer thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, provided as one aspect of the present invention, exhibits a high inhibitory ability on euchromatic histone-lysine N-methyltransferase 2 (EHMT2), and thus, the compound can be usefully used for the treatment of cancer.

Abstract: A liquid crystal display device includes first and second substrates facing and spaced apart from each other; a liquid crystal layer between the first and second substrates; a thin film transistor in a subpixel on an inner surface of first substrate; a pixel electrode connected to the thin film transistor; a common electrode generating an electric field with the pixel electrode; a black matrix in a border portion of the subpixel on an inner surface of the second substrate, the black matrix including a metallic material, and a voltage applied to the black matrix; and a color filter layer in a center portion of the subpixel on the black matrix.

Abstract: A liquid crystal display device including a liquid crystal panel including a first substrate, a thin film transistor on the first substrate, an organic buffer layer between the first substrate and the thin film transistor, a second substrate, a color filter layer on the second substrate, and a liquid crystal layer between the first and second substrates, and a backlight unit below the liquid crystal panel. The second substrate is between the backlight unit and the first substrate.

Abstract: The present invention relates to a method for preparing a biomaterial having selectively functionalized tyrosine, a biomaterial having selectively functionalized tyrosine, and a pharmaceutical composition containing the same as an active ingredient. The method for preparing a biomaterial to which a compound represented by formula 2 is coupled, of the present invention, allows the compound represented by formula 2 to be selectively coupled, in a high yield in a biomaterial, to tyrosine, which is present on the surface of an aqueous solution such that the coupling thereof to amino acids other than tyrosine does not occur and, when only one tyrosine is present, heterogeneous mixtures are not present and the inherent activity of the biomaterial is maintained, and thus the compound can be effectively used as a pharmaceutical composition containing a biomaterial drug as an active ingredient.

Abstract: Provided are: a novel pyrrolidine derivative or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing same and having the effects of inhibiting beta-amyloid and/or tau protein aggregation, and/or breaking down beta-amyloid and/or tau protein aggregates, and/or preventing and/or treating beta-amyloid and/or tau protein-associated diseases.

Abstract: Provided is a novel compound and a use thereof. A novel compound according to the presently claimed subject matter induces the activation of MKP-1 protein to block the cellular signaling pathway proceeding in the order of p38/CK2?/NF-?B, thereby very effectively inhibiting an inflammatory response occurring in a respiratory disease. Therefore, a respiratory disease can be prevented, alleviated, or treated by orally administering the novel compound according to the presently claimed subject matter.

Abstract: The present invention relates to a compound comprising an EZH2 inhibitor and an E3 ligase binder, and a pharmaceutical composition for preventing or treating EZH2-associated disease and a pharmaceutical composition for selective protein degradation containing the same as an active ingredient. Since the compound of the present invention can selectively degrade EZH2, it can be effectively used for the treatment of EZH2-related diseases and cancers, particularly, cancers in which EZH2 is overexpressed, and can be usefully used for the selective degradation of EZH2.

Abstract: A liquid crystal display device includes first and second substrates facing and spaced apart from each other; a liquid crystal layer between the first and second substrates; a thin film transistor in a subpixel on an inner surface of first substrate; a pixel electrode connected to the thin film transistor; a common electrode generating an electric field with the pixel electrode; a black matrix in a border portion of the subpixel on an inner surface of the second substrate, the black matrix including a metallic material, and a voltage applied to the black matrix; and a color filter layer in a center portion of the subpixel on the black matrix.

Abstract: Provided is a 2-cyanopyrimidin-4-yl carbamate or urea derivative or pharmaceutically acceptable salt thereof, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The 2-cyanopyrimidin-4-yl carbamate or urea derivative or pharmaceutically acceptable salt thereof selectively inhibits cathepsin K and therefore can be usefully applied for preventing or treating osteoporosis.

Abstract: A novel organic sulfur compound, a method for preparing the same, and a pharmaceutical composition for preventing or treating cancer or inflammatory diseases, containing the same as an active ingredient are provided. The novel organic sulfur compound is capable of excellently inhibiting histone deacetylated (HDAC) enzymes in a concentration of nanomolar or micromolar units and has been found to have an excellent effect against inflammatory diseases, and has been found to be capable of inhibiting the proliferation of cancer.

Abstract: A novel organic sulfur compound, a method for preparing the same, and a pharmaceutical composition for preventing or treating cancer or inflammatory diseases, containing the same as an active ingredient are provided. The novel organic sulfur compound is capable of excellently inhibiting histone deacetylated (HDAC) enzymes in a concentration of nanomolar or micromolar units and has been found to have an excellent effect against inflammatory diseases, and has been found to be capable of inhibiting the proliferation of cancer.

Abstract: Provided is a 2-cyanopyrimidin-4-yl carbamate or urea derivative or pharmaceutically acceptable salt thereof, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The 2-cyanopyrimidin-4-yl carbamate or urea derivative or pharmaceutically acceptable salt thereof selectively inhibits cathepsin K and therefore can be usefully applied for preventing or treating osteoporosis.